Los Angeles, October 7 Patients with KRAS-mutant advanced pancreatic cancer now have a treatment that nearly doubles survival time, according to recent clinical trial data. Daraxonrasib, approved by the FDA, achieved a median overall survival of 13.2 months — compared to 6.6 months for those on chemotherapy — marking a significant leap in oncology. The breakthrough follows the 2013 discovery of the G12C variant in the KRAS gene, which led to the development of sotorasib, the first KRAS inhibitor.
This drug transformed treatment options for some patients with non-small cell lung cancer, proving that KRAS — long considered ‘undruggable’ — could be targeted with precision medicine. Approximately 95% of pancreatic adenocarcinomas harbor KRAS mutations, though these often involve different variants than those targeted in lung cancer therapies.
The foundational work from the lung cancer breakthrough enabled the development of daraxonrasib, which is now showing promise in pancreatic cancer. Researchers David Shackelford, PhD, and Alex Jaeger, PhD, both recipients of Lung Association grants, have contributed to understanding resistance mechanisms and immune responses following KRAS inhibition. Their work has identified new antigens recognizable by T cells, supporting ongoing efforts to combine KRAS inhibitors with immunotherapies.
The progression from lung cancer discovery to pancreatic cancer treatment illustrates how initial investments in biomarker research and targeted therapy development can yield broader oncology advances. This has implications for future drug development and healthcare investment in precision medicine.
Investors will note that the success of KRAS inhibitors in lung cancer has spurred a wave of research into other KRAS mutations and cancers driven by the broader RAS gene family. This could lead to further breakthroughs in oncology, with potential economic and healthcare impacts. As the field continues to evolve, the focus will remain on expanding the application of KRAS inhibitors to other cancers and improving outcomes through combination therapies.
The coming years may see more approvals and a broader impact on precision medicine.
